Navigation Links
Lumeda Enters License Agreement with Roswell Park Comprehensive Cancer Center
Date:6/28/2020

Lumeda Inc. (“Lumeda”), a biophotonics systems company formed to advance photodynamic therapy for treating cancer, today announced the company has entered a license agreement with Roswell Park Comprehensive Cancer Center of Buffalo, New York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual property surrounding a novel medical device and method for intraoperative photodynamic therapy (IO-PDT), which can be used for treating non-small cell lung cancer (NSCLC).

PDT is an established treatment for a range of cancers but, despite its promise in NSCLC, its broad adoption is hindered by its current treatment delivery mode that is difficult to perform with inconsistent results. The Roswell Park innovation enables a simplified and more effective IO-PDT procedure that could be added to the Standard of Care in NSCLC tumor resection.

“Entering this agreement marks the start of refinement and ultimate introduction of this important lung cancer therapy to the clinic,” according to Trevor MacDougall, one of the founders of Lumeda. “This agreement fosters further collaboration between the world’s leading PDT center and Lumeda’s proven photonics product development team.”

Under the agreement, Lumeda will apply its photonics design and development capabilities to commercialize a complete automated IO-PDT solution.

Photodynamic therapy (PDT) was developed at Roswell Park, which remains a worldwide leader in PDT research and clinical application as a treatment for many types of cancer.

About Roswell Park Comprehensive Cancer Center:
Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

About Lumeda:
Lumeda is advancing PDT to treat NSCLC and other thoracic malignancies. The company applies advanced photonics and proprietary software to automate and digitize PDT light delivery to improve PDT efficacy, ease of use, and treatment planning. The multidisciplinary Lumeda team has decades of experience in the photonics industry, with significant expertise and strength in systems engineering, factory operations, and the commercialization of new products and technology. Lumeda is committed to pioneering the advancement and utility of PDT for improved patient outcomes. For more information, please visit http://www.lumedainc.com.

Read the full story at https://www.prweb.com/releases/lumeda_enters_license_agreement_with_roswell_park_comprehensive_cancer_center/prweb17218726.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Next Generation Protein Sequencing Company Rapid Novor Enters into New Phase of Growth
2. IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
3. Bio-Tech Firm PathSensors Enters Fast-Growing Chinese Pathogen Detection Market
4. MMJ International Holdings Enters Cannabis Study Agreement with BioInformatics and Genomics Center (BIG) at the University of Buffalo, New York
5. Research Centers of America Adopts Verified Clinical Trials Biometrics Research Subject Database Registry to Prevent Duplicate Enrollment in Clinical Trials
6. Inspirata to Exhibit at CANCERSCAPE 2017 in Washington DC to Help Community Cancer Centers Better Bridge the Gap Between Pathology and Precision Medicine
7. Northwest Kidney Centers Announces Intention to Grant $15 Million to Jumpstart UW Medicines Center for Dialysis Innovation
8. Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties
9. Enteris BioPharma Enters Agreement with Sanofi to Develop Investigational Oral Therapeutic for Type 2 Diabetes
10. FireflySci Enters Fiber Optic Probe Market With Several New Offerings
11. Back Pain Centers Of America Calls For Award Submissions For Excellence In Spine Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2020)... ... August 03, 2020 , ... ... Jim Corrigan, President and CEO has been named one of the 100 most ... industry sectors, PharmaVoice 100 honorees are selected based on how they have inspired ...
(Date:7/31/2020)... ... July 29, 2020 , ... Diversified Technologies, Inc. ... can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. , DTI ... two switches in a push-pull configuration; yielding fast fall time for a capacitive ...
(Date:7/31/2020)... ... July 29, 2020 , ... The ... centers in 16 countries, has reached its 20th anniversary of worldwide use. Introduced ... use at top universities including University of Pennsylvania, University of Michigan, University of ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this ... the only technology of its kind on the market and we were pleased that ... protective capacity of traditional cultured ingredients, creating a natural way to extend the shelf ...
Breaking Biology Technology:
(Date:8/21/2020)... ... 20, 2020 , ... NDA Partners Chairman Carl Peck, ... with expertise in clinical trial planning and feasibility, regulatory inspection readiness, and clinical ... his career, Mr. Movahhed has helped design and manage oncology, neurology, cardiovascular, and ...
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from ... and ProText™, making them the first Wharton’s jelly allografts to be assigned a Q ... company’s solutions are the first Wharton’s jelly allograft product to be recognized as a ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study ... the Invictus Medical Neoasis™ active noise control device to attenuate typical noises in ... Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and other bedside ...
Breaking Biology News(10 mins):